SPS
RARE icon

Susquehanna Portfolio Strategies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,147
Closed -$294K – 465
2024
Q2 		$294K Sell
7,147
-17,000
-70% -$726K 0.01% 426
2024
Q1 		$1.13M Hold
24,147
– – 0.03% 427
2023
Q4 		$1.15M Buy
+24,147
New +$936K 0.02% 563

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Susquehanna Portfolio Strategies's RARE Position: Q3 2024 in Review

Susquehanna Portfolio Strategies sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 7,147 shares — an estimated $294K sold.

Susquehanna Portfolio Strategies first reported a position in RARE in Q4 2023 and held it in 3 quarters. The position peaked at $1.15M in Q4 2023. 301 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Susquehanna Portfolio Strategies reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 7,147 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $294K.
  • Susquehanna Portfolio Strategies first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 3 quarters.
  • Susquehanna Portfolio Strategies's Ultragenyx Pharmaceutical position peaked at $1.15M in Q4 2023.
  • 301 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.